Mind-NRG is developing NRG-101, a neuregulin-based neurotrophic factor that naturally crosses the blood–brain barrier and is intended to have disease-modifying effects in central nervous system disorders. NRG-101 is being investigated pre-clinically for early-stage neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, as well as schizophrenia, and has been shown to target multiple disease mechanisms. The company plans to use its recent funding to elucidate the mechanism of NRG-101’s neuroprotective effect in Parkinson’s disease and to advance the compound toward proof-of-concept studies in patients. Mind-NRG emphasizes that NRG-101’s multi‑mechanistic action sets it apart from compounds that inhibit single targets or pathways. The company is venture-backed, was founded in 2010, and is based in Switzerland. Recent financing activity strengthens its position to move from pre-clinical work toward clinical proof-of-concept. Mind-NRG is a Switzerland-based company focused on developing a peptidic neurotrophic factor, NRG-101. The company is advancing NRG-101 as a potential treatment for neurological and psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease and schizophrenia. Initial work will concentrate on pivotal in vitro and in vivo experiments to explore the peptide’s mechanism of action and assess activity across relevant disease models. ProteoSys, a Mainz, Germany-based research company, developed and validated NRG-101 and assigned the asset to Mind-NRG in exchange for equity in the newly formed company. Financially, Mind-NRG closed an up to €10m financing with Index Ventures; Index had already invested €1.5m to generate further key data. The program is being advanced under an asset-centric model emphasized by its lead investor.

Total raised

$22M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2013